KERYX Biopharmaceuticals, Inc.

Product candidate Target indication Development status

Zerenex^TM (ferric citrate) Hyperphosphatemia in patients with end-stage renal disease Phase 3 Completed Jan 2013; Pending NDA and MAA submissions.

Japan Phase 3 program completed by sublicensee (JT and Torii); Japanese NDA filed Jan 2013.

Zerenex^TM (ferric citrate) Management of serum phosphorus and iron deficiency in anemic patients with Stage 3 to 5 non-dialysis dependent chronic kidney disease ("NDD-CKD") Phase 2 initiated Nov 2012; Ongoing.

Disclaimer: These investigational drug products have not been approved by the US Food and Drug Administration for safety and effectiveness. These investigational drug products are still undergoing clinical study to verify their safety and effectiveness